Investors Purchase Large Volume of TransMedics Group Put Options (NASDAQ:TMDX)

Key Points

• Put-option activity surged: Traders purchased 17,429 TransMedics Group put options, nearly five times the typical volume, signaling unusually high hedging or bearish interest.
• Director David Weill bought 1,336 shares at an average price of $81.63, increasing his ownership by 8.87%; institutional investors own 99.67% of the company.
• Analysts maintain a mixed outlook, with an average rating of Hold and a consensus price target of $121.10. TMDX rose 1.1% to $84.83, while its latest revenue exceeded estimates despite an earnings-per-share miss.

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) was the recipient of unusually large options trading on Friday. Traders acquired 17,429 put options on the stock. This is an increase of 493% compared to the typical volume of 2,937 put options.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director David Weill acquired 1,336 shares of the company's stock in a transaction dated Friday, September 11th. The shares were bought at an average cost of $81.63 per share, with a total value of $109,057.68. Following the purchase, the director directly owned 16,392 shares of the company's stock, valued at $1,338,078.96. This trade represents a 8.87% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 6.90% of the company's stock.

Institutional Investors Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently made changes to their positions in the business. Envestnet Portfolio Solutions Inc. increased its holdings in TransMedics Group by 77.3% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 7,691 shares of the company's stock worth $511,000 after purchasing an additional 3,352 shares in the last quarter. WINTON GROUP Ltd boosted its holdings in TransMedics Group by 52.4% during the second quarter. WINTON GROUP Ltd now owns 18,203 shares of the company's stock worth $1,209,000 after purchasing an additional 6,262 shares during the last quarter. Integrated Wealth Concepts LLC grew its holdings in shares of TransMedics Group by 31.3% in the second quarter. Integrated Wealth Concepts LLC now owns 2,877 shares of the company's stock valued at $191,000 after acquiring an additional 686 shares in the last quarter. IFP Advisors Inc grew its holdings in shares of TransMedics Group by 4.8% in the second quarter. IFP Advisors Inc now owns 4,652 shares of the company's stock valued at $309,000 after acquiring an additional 213 shares in the last quarter. Finally, Corient Private Wealth LP increased its position in shares of TransMedics Group by 123.2% during the second quarter. Corient Private Wealth LP now owns 19,285 shares of the company's stock valued at $1,281,000 after acquiring an additional 10,644 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

TMDX has been the subject of a number of research analyst reports. Piper Sandler reiterated an "overweight" rating and issued a $100.00 target price (down from $120.00) on shares of TransMedics Group in a report on Wednesday, August 5th. Needham & Company LLC reaffirmed a "buy" rating on shares of TransMedics Group in a research report on Friday, September 11th. Canaccord Genuity Group reiterated a "buy" rating and issued a $124.00 price objective on shares of TransMedics Group in a research note on Tuesday, June 30th. Weiss Ratings upgraded shares of TransMedics Group from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, August 31st. Finally, Stifel Nicolaus increased their target price on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a "hold" rating in a research note on Thursday, June 18th. Five investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, TransMedics Group currently has an average rating of "Hold" and a consensus price target of $121.10.

TransMedics Group Stock Up 1.1%

NASDAQ:TMDX traded up $0.93 on Friday, hitting $84.83. The stock had a trading volume of 347,883 shares, compared to its average volume of 1,018,254. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. TransMedics Group has a 52 week low of $60.10 and a 52 week high of $156.00. The business's fifty day moving average is $84.46 and its 200 day moving average is $86.88. The company has a market cap of $2.93 billion, a PE ratio of 21.84, a P/E/G ratio of 1.21 and a beta of 1.90.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm had revenue of $189.95 million for the quarter, compared to analyst estimates of $184.00 million. During the same period in the previous year, the company earned $0.92 earnings per share. TransMedics Group's revenue for the quarter was up 20.7% compared to the same quarter last year. On average, equities research analysts expect that TransMedics Group will post 1.46 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. The company develops and commercializes organ preservation and transport technologies designed to maintain donor organs in a functioning condition outside the body, potentially supporting evaluation and extending the time available for transplantation.

Its primary product is the Organ Care System (OCS), a portable perfusion platform that circulates oxygenated, nutrient-enriched fluid through donor organs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.